Drug delivery vehicles can improve the functional efficacy of existing antimicrobial therapies by improving biodistribution and targeting. A critical property of such nanomedicine formulations is their ability to control the release kinetics of their payloads. The combination of (and interactions between) polymer, drug, and nanoparticle properties gives rise to nonlinear behavioral relationships and a large data space. These factors complicate both first-principles modeling and screening of nanomedicine formulations. Predictive analytics may offer a more efficient approach toward rational design of nanomedicines by identifying key descriptors and correlating them to nanoparticle release behavior. In this work, antibiotic release kinetics data were generated from polyanhydride nanoparticle formulations with varying copolymer compositions, encapsulated drug type, and drug loading. Four antibiotics, doxycycline, rifampicin, chloramphenicol, and pyrazinamide, were used. Linear manifold learning methods were used to relate drug release properties with polymer, drug, and nanoparticle properties, and key descriptors were identified that are highly correlated with release properties. However, these linear methods could not predict release behavior. Non-linear multivariate modeling based on graph theory was then used to deconvolute the governing relationships between these properties, and predictive models were generated to rapidly screen lead nanomedicine formulations with desirable release properties with minimal nanoparticle characterization. Release kinetics predictions of two drugs containing atoms not included in the model showed good agreement with experimental results, validating the model and indicating its potential to virtually explore new polymer and drug pairs not included in training data set. The models were shown to be robust after inclusion of these new formulations in that the new inclusions did not significantly change model regression. This approach provides the first steps towards development of a framework that can be used to rationally design nanomedicine formulations by selecting the appropriate carrier for a drug payload to program desirable release kinetics. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 2 ABSTRACT Drug delivery vehicles can improve the functional efficacy of existing antimicrobial therapies by improving biodistribution and targeting. A critical property of such nanomedicine formulations is their ability to control the release kinetics of their payloads. The combination of (and interactions between) polymer, drug, and nanoparticle properties gives rise to nonlinear behavioral relationships and a large data space. These factors complicate both first-principles modeling and screening of nanomedicine formulations. Predictive analytics may offer a more efficient approach toward rational design of nanomedicines by identifying key descriptors and correlating them to nanoparticle release behavior. In this work, antibiotic release kinetics data were generated from polyanhydride nanoparticle formulations with varying copolymer compositions, encapsulated drug type, and drug loading. Four antibiotics, doxycycline, rifampicin, chloramphenicol, and pyrazinamide, were used. Linear manifold learning methods were used to relate drug release properties with polymer, drug, and nanoparticle properties, and key descriptors were identified that are highly correlated with release properties. However, these linear methods could not predict release behavior. Non-linear multivariate modeling based on graph theory was then used to deconvolute the governing relationships between these properties, and predictive models were generated to rapidly screen lead nanomedicine formulations with 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 3 framework that can be used to rationally design nanomedicine formulations by selecting the appropriate carrier for a drug payload to program desirable release kinetics.
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framework that can be used to rationally design nanomedicine formulations by selecting the appropriate carrier for a drug payload to program desirable release kinetics.
INTRODUCTION
Intracellular bacterial infections are challenging to treat using traditional antimicrobial therapies due to the difficulty in achieving high enough local drug concentration for antimicrobial activity without inducing host cell toxicity. 1 Elimination of soluble drugs through host metabolism and excretion pathways act to reduce bioavailable amounts of antimicrobials requiring repeated dosing to maintain therapeutic concentrations to mitigate the development of antibiotic resistant in pathogens. 2, 3 Drug delivery vehicles can improve the efficacy and potency of antimicrobials by altering the drug biodistribution with improved intracellular localization and delivery of cargo to the pathogen's intracellular niche within host cells. 4, 5 Biodegradable polyanhydride nanoparticles show passive targeting and payload stabilization properties that make them uniquely suited for antibiotic delivery for intracellular infections. 4, 6 These particles are internalized efficiently by phagocytic cells using multiple mechanisms, and have been used to deliver antibiotics to kill intracellular Brucella abortus. 7 Additionally, polyanhydride nanoparticles mediated efficient killing of filarial parasites by co-delivering an antiparasitic with an antibiotic targeting an intracellular endosymbiotic bacterium that supports parasite health and reproduction. 8 A key feature of the effectiveness of these nanomedicine formulations is their ability to control payload release rate, however rationally designing nanomedicines with programmable release remains elusive. Release kinetics are influenced by drug distribution within a device and/or a particle, which is in turn influenced by polymer-drug thermodynamic interactions. [9] [10] [11] These interactions give rise to nonlinear release behavior which is difficult to predict a priori.
Screening nanomedicine formulations is challenging as polymer and nanoparticle properties (e.g., polymer chemistry, nanoparticle size, polydispersity, release kinetics, and encapsulation efficiency) yield a large number of additional variables beyond drug-specific properties. This large dataspace, coupled with the multiple length scales at play, poses difficulties for generalizing conclusions to other nanoparticle systems and impedes first principles modeling of nanoparticle behavior. 12, 13 Hierarchical modeling may be a more efficient approach for such systems, wherein key descriptors are identified and correlated to performance parameters.
Informatics methods encompass several tools for such hierarchical modeling. Data mining techniques can deconvolute complex behavior, unraveling relationships that lie on non-Euclidian surfaces, 14 which enables pattern recognition and prediction through the development of quantitative structure-property relationships (QSPRs). 15 To this end, previous informatics analyses from our laboratories has enabled identification of polyanhydride chemistry and structural factors that influence protein release from films 16 and enable pathogen-mimicking nanoparticle processing by immune cells. [17] [18] [19] [20] The focus of this work was to develop an informatics-based framework that determines how polymer, drug, and nanoparticle characteristics influence drug encapsulation efficiency and release kinetics. We sought to generate predictive models that can virtually test potential new polymer and drug combinations for desirable release kinetics. Our long-term goal is to develop a predictive analytics framework to enable rational design of nanomedicine formulations for different types of therapeutic and prophylactic applications.
MATERIALS AND METHODS

Materials. Sebacic acid (SA) was purchased from Sigma Aldrich (St. Louis, MO).
Triethylene glycol, 4-p-hydroxybenzoic acid, 1-methyl-2-pyrrolidinone, and 1,6-dibromohexane were purchased from Sigma Aldrich for 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and 1,6-bis(p-carboxyphenoxy)hexane (CPH) monomer synthesis. Potassium carbonate, dimethyl formamide, toluene, acetonitrile, acetic acid, sulfuric acid, N,N-dimethylacetamide, and acetic anhydride were purchased from Fisher Scientific (Fairlawn, NJ) for monomer and polymer synthesis. 4-p-fluorobenzonitrile was purchased from Apollo Scientific (Cheshire, UK) for use in monomer synthesis. Methylene chloride, pentane, and hexanes were purchased from Fisher Scientific for polymer purification and nanoparticle synthesis. Doxycycline (DOX), rifampicin (RIF), and pyrazinamide (PZA) were purchased from Sigma Aldrich, and chloramphenicol (CAM) was purchased from Fisher Scientific. Meropenem (MEM) was purchased from Ark Pharm, Inc. (Arlington Heights, IL) and ceftazidime (CAZ) was purchased from Acros Organics (NJ). 1 H NMR analysis used deuterated chloroform purchased from Cambridge Isotope Laboratories (Andover, MA). Drug quantification used UV-transparent microplates from Greiner Bio-One (Kremsmünster, Austria), HPLC grade acetonitrile, methanol, and tetrahydrofuran from Fisher Scientific, and phosphoric acid from Sigma Aldrich.
2.2.
Polymer and nanoparticle synthesis. CPTEG and CPH diacid were synthesized as described previously. 10, 21, 22 CPTEG:CPH and CPH:SA copolymers were synthesized as described previously. 10, 21 Briefly, monomers were weighed in appropriate molar ratios and added to a round bottom flask. The monomers were acetylated in excess acetic acid at 125°C for 30 min, and rotary evaporation was used to remove excess solvent from the resulting prepolymer.
CPTEG:CPH was reacted for six hours at 140°C at <0.1 Torr and CPH:SA was reacted for 30 min at 180°C at <0.3 Torr. Polymers were purified by precipitation in chilled hexanes.
Copolymer composition and number average molecular weight (M n ) was confirmed from 1 H 6 NMR spectra acquired on a Varian MR-400 (Varian, Inc. Palo Alto, CA) and thermal properties of the copolymers was characterized by DSC (Q2000, TA Instruments, New Castle, DE).
Antibiotic-loaded nanoparticles were synthesized as described previously. 7, 8 Polymer and drug were weighed in separate scintillation vials at appropriate %w/w ratios. Enough methylene chloride to dissolve the polymer at 20 mg/mL was added to the drug vial to dissolve/disperse the drug, then transferred to the polymer vial. The combined drug and polymer solution was poured into a pentane antisolvent bath at room temperature (CPH:SA) or -10°C (CPTEG:CPH) at a solvent:anti-solvent ratio of 1:250 and nanoparticles were recovered by vacuum filtration.
CPTEG:CPH nanoprecipitation was carried out in a cold room at 4°C. A total of 68 nanoformulations were tested, spanning drug loadings between 1% and 20% loading (% w/w). To validate the informatics analysis, nanoparticles encapsulating meropenem or ceftazidime were synthesized using a high-throughput method adapted from Goodman et al. 23 Briefly, polymer and drugs were dissolved/dispersed in methylene chloride and dispensed via highthroughput robot into 10 mL borosilicate tubes at a final polymer concentration of 20 mg/mL.
The robot sonicated and dispensed the combined polymer and drug solution into 50 mL conical polypropylene tubes containing 45 mL pentane (1:18 solvent:anti-solvent ratio) at the temperatures listed above. Multiple particle batches were pooled and recovered by vacuum filtration. Scanning electron microscopy (SEM, FEI Quanta 250, Hillsboro, OR) was used to image all nanoparticles, and size distributions were calculated using Fiji image analysis 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 software 24 and the ParticleSizer plugin script for Fiji. Nanoparticle zeta potential was measured using a Zetasizer Nano (Malvern Instruments Ltd., Worcester, UK).
2.
3. Drug release kinetics. Nanoparticles (9-11 mg) were dispersed in 0.5 mL PBS, pH 7.4 and suspended by sonication (VCX 130 PB, Sonics & Materials, Inc., Newtown, CT). At each time point, the nanoparticles were pelleted by centrifugation and supernatant was collected for drug quantification. Fresh PBS was added to maintain perfect sink conditions and the nanoparticles were dispersed by sonication. At the end of the release experiment, 40 mM sodium hydroxide was added to accelerate polymer degradation and extract the remaining encapsulated drug as described previously. 25 The drug mass released at each time point was determined by spectrophotometry (SpectraMax M3, Molecular Devices, San Jose, CA) and UV-HPLC (1200 series, Agilent Technologies, Santa Clara, CA). Doxycycline, rifampicin, and chloramphenicol were quantified by absorbance in UV-transparent 96-well plates at 350, 333, and 293 nm, respectively. Pyrazinamide release and base extraction samples were separated using a Phenomenex Kinetex 2.6-micron C18 100Å 100x4.6mm column and a 30:5:65 acetonitrile:methanol:water mobile phase adjusted to pH 5.2 with phosphoric acid. 26 The flow rate was 0.6 mL/min and pyrazinamide was quantified at 268 nm. Meropenem and ceftazidime release and base extraction samples were separated using a Zorbax Eclipse XDB-C8 5-micron 4.6x150 mm column, monitoring at 299 nm and 246 nm, respectively. Meropenem release samples used a mobile phase gradient ramping from 0.1/99.9 (%v/v) methanol/water to 50/50 over 15 min. Meropenem base extraction samples used a gradient ramping from 0.1/99.9 acetonitrile 0.1% trifluoroacetic acid/ water 0.1% trifluoroacetic acid to 50/50 over 15 min. Ceftazidime release samples used a mobile phase protocol with an isocratic step at 0.1/99.9 methanol/water for 5 minutes followed by a gradient ramping to 50/50 acetonitrile 0.1% trifluoroacetic acid/ water 0.1% trifluoroacetic acid for 1 min followed by a gradient ramping to 40/60 over 5 min. All meropenem and ceftazidime HPLC protocols used a flow rate of 1 mL/min.
The small mass of drug and large volume of antisolvent used in nanoparticle synthesis render the non-encapsulated drug concentration below the limit of detection of the analytical methods used in this study. Therefore encapsulation efficiency (EE) was calculated from the cumulative sum of detected drug mass released in PBS and base extraction samples using Eq. 1. 25 In a minority of formulations >100% EE was observed, which could arise from the presence of drug nanocrystals 27 (which was not detected on nanoparticle surfaces by SEM), gravimetric inaccuracies due to static charge of the nanoparticles, or residual error in the drug concentration quantification assays. Drug release kinetics are presented as fraction released, where the cumulative drug mass release is normalized by the total encapsulated drug mass. Prism 7 (Graphpad Software, La Jolla, CA) was used to generate release kinetics figures. In order to model the drug release properties accurately and robustly, we found that non-linearity needed to be accounted for in the modeling. Therefore, we first developed non-linear parameterization of the data through non-linear manifold learning, based on graph theory, using the Isomap algorithm. 14, 35 This approach generates a graph connecting data points on a high dimensional space to their nearest neighbors, mapped out in the high dimensional space, and then fit to a low dimensional manifold. The assumption here is that the graph Euclidean distance between the points in high dimensions closely approximates the curvilinear distances along the low dimensional manifold. Through dimensionality reduction the manifold unravels into two or three dimensions allowing it to be visualized. The result of such dimensionality reduction is a weighted graph of the original data points where the edges are weighted according to the geodesic distances. Like in PCA, we develop a set of parameters for each set of conditions, although in this case the parameters are based on a non-linear combination of descriptors.
RESULTS
Building descriptor library.
To generate the data set, we focused on nanoparticles composed of CPTEG, CPH, and SA copolymers (Figure 1 a,b). Nanoparticles synthesized from these polyanhydride copolymers have been shown to kill intracellular bacteria because of their high internalization rates by phagocytic cells, 7, 36 localization in intracellular compartments that harbor these bacteria, 17, 36 and improved antimicrobial activity of encapsulated drugs. [6] [7] [8] In addition to the structural descriptors defined by Li et al., 16 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 database. 37 Predicted drug properties from this database were calculated by ALGOPS and ChemAxon methodologies.
These drugs were encapsulated in polyanhydride nanoparticles by flash nanoprecipitation, and zeta potential, size distributions, and polydispersity index were obtained. Release profiles and encapsulation efficiencies were obtained from in vitro experiments in PBS, pH 7.4 ( Figure 2 ). add to the body of literature [9] [10] [11] 38 that indicates that copolymer chemistry, drug type, and drug loading influence drug release kinetics from biodegradable particles and other devices. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Structure of doxycycline (DOX, a), rifampicin (RIF, b), chloramphenicol (CAM, c), and pyrazinamide (PZA, d). Release profiles were parameterized into two-hour burst, one day burst, and 2-7 day sustained release slope. 
Identifying Factors that Influence Drug Release.
The drug release profiles were parameterized using three attributes: (i) fraction released at two hours (FR (2h)); (ii) fraction released in one day (FR (24h)), both of which characterized the burst effect; and (iii) the slope of the release profile between 2 and 7 days to characterize the sustained release (Table 1) . The normalized and mean-centered data are represented in the form of a heat map to provide an overview and to ensure that no outliers are biasing the results ( Figure 3 , Table S1 -2). In this step, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 no data specific to particle chemistry was included so as to not bias the analysis. A clustering analysis, based on Euclidian distance, was used to visualize broad trends in the data set between descriptors and nanoformulations, and is represented in Figure 3 From Figure 3 , we find that the primary difference is between CPH:SA and CPTEG:CPH, given that the two chemistries branch off at the lowest correlation node. Therefore, particle chemistry is the key discriminator for nanoformulation behavior. Within each node, the compounds then group based on drug type, and then finally branch off based on theoretical drug loading and molar monomer ratios within the copolymer. This defines the order of importance on release 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 and zeta potential. The fraction released/day clustered with nanoparticle diameter and PDI polymer DOP and M n . The relatively low branching of these properties in the dendrogram indicates moderate to strong correlation. Encapsulation efficiency (EE) was most strongly correlated with water solubility, followed by fraction released/day. This (weak) correlation to water solubility is expected, as incompatibility between polymer and drug hydrophobicity/hydrophilicity can result in drug partitioning more strongly in the antisolvent than the polymer matrix. The drug release properties (burst release, slope of release, and encapsulation efficiency) appeared relatively isolated from each other within the dendrogram, suggesting potential for independent control of these properties in designing nanoformulations. From the dendrograms, the key discriminators among nanoformulations (vertical axis) in the order of importance are carrier chemistry (CPTEG:CPH versus CPH:SA), drug type, and Tables S1-2. A dimensionality reduction analysis, specifically principal component analysis (PCA), was then applied to the data of Figure 3 , with descriptors specific to the particle and drug chemistry added to the data set (Table S3 ). Plots of formulation mapping and descriptor mapping within the dimensionally-reduced space are shown in Figures 4 and 5 , respectively. In these figures, the principal components (PC) are ordered in terms of decreasing variability captured. PC1, the most important PC, captured particle chemistry properties (41.3%); therefore, differences in particle chemistry descriptors explain more variance in release behavior than other descriptor sets. The next most important PC, PC2, captured differences in drug-specific descriptors (27.9%). The scores plot (Figure 4 ), which maps individual nanoparticle formulations onto these PC's (which, between them, allow us to reliably capture correlations in those two dimensions), shows a clear separation between CPTEG:CPH and CPH:SA particle chemistries. Within each polymer, doxycycline, chloramphenicol, and pyrazinamide clustered together, whereas rifampicin formulations formed a cluster isolated from the other drugs, indicating potentially different types of interactions with the particle carriers. The loadings plot ( Figure 5 ), which maps the descriptor variables onto the PC's shows that the role of the particle and the drug bank descriptors have been isolated (i.e., particle data lies along the PC1 axis and drug bank data is along the PC2 axis). Given that PC1 is the most important axis, we are capturing that the particle chemistry is the critical characteristic for predicting particle release behavior. The drug release properties do not adhere exclusively to either PC1 or PC2 axes, indicating that they are influenced by both polymer and drug characteristics. The ability to isolate the different controls allows us to assess, model, and design by the material characteristics. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 chemistries, with a demonstrated capability to isolate the effects of particle chemistry from drug properties. PC1 and PC2 captured 43.1% and 27.9% of variability, respectively. Drug abbreviations: doxycycline (DOX), rifampicin (RIF), chloramphenicol (CAM), and pyrazinamide (PZA). Raw input data are provided in Table S3 . Figure 5 . PCA loadings plot. Particle descriptors lie along the PC1 axis and drug descriptors lie along the PC2 axis. Drug release properties lie along both axes, indicating some dependence on both particle and drug descriptors. PC1 and PC2 captured 43.1% and 27.9% of variability, respectively. Raw input data are provided in Table S3 .
To further quantify the correlation between descriptors and release properties, we calculated the VIP. In all, a total of 36 descriptors were used in the VIP analysis (as shown in Table 2 ), describing nanoparticle (1-3), polymer (4-13), and drug properties . The encapsulation efficiency was most strongly correlated with zeta potential (-), % Cl (drug) (+), % O (drug) (+), T m,drug (-), predicted water solubility (-), pKa (strongest base) (-), and drug rotatable bond count (+). As seen in Figure 3 , the two-hour burst and slope of release were highly correlated with each other, and showed similar correlations with the descriptors. Both the two-hour burst and slope of release were most strongly correlated with % Cl (drug) (+), % O (drug) (+), water solubility (-), % N (drug) (-), pKa (strongest acid) (-), and rotatable bond count (+). The identification of several highly correlated descriptors allows for reduction of the descriptor space to a minimum number and defines the number of descriptors necessary for performing high throughput calculations. This minimization is an important objective in computational modeling to improve model robustness. The purpose of VIP analysis is to assess the descriptors that contribute significant information as well as to identify correlated descriptors. While we identify the drugrelated descriptors as having the highest individual impact, the particle-related descriptors collectively contribute the largest amount of information as seen in Figure 4 . Descriptors are listed in Table 2 . Positive VIP values correspond to positive correlation, and negative values to inverse correlation. 
Modeling release behavior.
Beyond only observing the correlation of data, we wanted to identify similarities and design pathways between the various nanoformulations. This connectivity defines samples which have the most similar behavior and can provide information on potential replacements and design. In order to accomplish this, we performed a graph theory analysis ( Figure 7 ). For the CPH:SA particle chemistries, there is a high connectivity (illustrated by black lines) and tight clustering within individual drugs. For the CPTEG:CPH particle chemistries, chloramphenicol, doxycycline, and pyrazinamide showed a high internal connectivity, but rifampicin branched out significantly. Each drug showed some degree of connectivity between the CPH:SA and CPTEG:CPH particle chemistries and doxycycline appeared to be the most interconnected across particle chemistries.
The degree of similarity can be defined by the number of connections required to connect two points. The distance along the two-dimensional projection also indicates the similarity of formulations. Pyrazinamide and chloramphenicol generated the least similarity in release behavior, as they required 4-6 connections, and lie far from each other along the projection. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Within each particle chemistry, doxycycline showed the most similarity to rifampicin and pyrazinamide, and rifampicin showed the most similarity to doxycycline and chloramphenicol.
The branched region of the CPTEG:CPH-rifampicin nanoformulations indicates some dissimilarity from the other rifampicin nanoformulations and some unique behavior that will need to be explored more systematically using experiments. Of note, the rifampicin formulations with altered molar composition of CPTEG:CPH (from the 20:80 that makes up most of the data set) showed high similarity to the 20:80 CPTEG:CPH nanoformulations within the cluster. This would suggest that nano-carrier copolymer compositions can be interchanged within these rifampicin-loaded formulations without major impact.
This graph theory mapping in Figure 7 yielded notably different drug clustering within each nano-carrier chemistry compared to PCA (Figure 4 ). Rifampicin and chloramphenicol formulations are closely related in this map, while they were distant from each other in the PCA scores plot. Strikingly, chloramphenicol and pyrazinamide are most distant in the graph theory map, while they were clustered closely in the PCA scores plot. These clustering differences are likely due to PCA's limited ability to capture non-linear relationships. Non-linear modeling techniques like graph theory are better equipped to capture the non-linear release behavior arising from interactions between polymer and drug properties. In summary, the graph theory mapping defined similarity and connectivity between different nanoparticle formulations, while capturing non-linearity in relationships that can be lost in linear analysis. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 As PCA projects data onto a linear manifold, it has difficulty explaining non-linear relationships.
To this end, PCA demonstrated insufficient capability to accurately predict release properties in this data set. By contrast, graph theory can be used to project the data onto a non-linear manifold.
This provides high-throughput modeling that accounts for non-linearity without requiring so many terms as to reduce the robustness of analysis. Therefore, the input into the predictions defines the graph theory values of Figure 7 , which reflects a non-linear combination of descriptors, and a multi-linear regression between these values and the drug release properties was developed. It should be noted that the drug release properties were not included in the nonlinear parameterization used for the prediction input, because that would result in predicting a property as a function of itself. The result of the high throughput modeling is shown in Figure 8 .
This represents a model with non-linear parameters that are a function of nanoparticle chemistry and theoretical drug loading and is defined generally so as to be applied to a wide range of chemistries. These models are fairly accurate, with R 2 values ranging between 70.0% and 75.5%.
Cross validation was applied to ensure an even trade-off between robustness and accuracy. Since these methods are based on descriptors that can be generated for potential new nanoparticle formulations, the models provide a method to virtually explore a large search space. This method can guide experimentation by predicting target properties for a desired release profile, suggesting chemistries that match the targeted properties for testing. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 accounting for greater complexity in descriptor-property relationships while also increasing the robustness of the models. The models are reasonably accurate for all tested release properties.
Model validation.
To evaluate the robustness and accuracy of the multilinear models, nanoparticles encapsulating two new antibiotic drugs (not included in the training data set), meropenem and ceftazidime, were synthesized and characterized. Importantly, these drugs contain sulfur atoms ( Figure S4 ) which are not present in the four drugs used in the original model training. The models in Figure 8 were used to predict the release properties for these new formulations (Table 3) . Based on these predictions, it is expected that all eight formulations would show a high (>80%) burst release at 2h and 24h and minimal sustained release over d2-d7.
With the exception of the 20:80 CPH:SA-meropenem formulation, all other nanoformulations are expected to show near-100% encapsulation efficiency.
Strikingly, these predictions match experimental results closely. These new nano-formulations displayed similar release profiles characterized by a >90% burst release within two hours, followed by small amounts of drug released over the following two weeks ( Figure S5 , Table 3 ).
For this data set, the models tended to under-predict the burst release and over-predict the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 deviation from measured values for 20:80 CPTEG:CPH formulations, at circa 15-35% differences from the experimental values. Table 3 . Parameterized release properties of nanoparticles encapsulating two drugs (meropenem and ceftazidime) not included in training data set. FR (2h) fraction released in two-hour burst, FR (24h) fraction released in 24-hour burst.
To test the robustness of the models when adding new, untrained chemistries, eight nanoformulations were included in the models (compositional percentages were calculated including sulfur atoms, but without a separate descriptor for sulfur) and new regressions were calculated.
We found R 2 values for EE, FR (2h), FR (24h) and d2-d7 slope after these inclusions to be 74.3%, 75.5%, 69.9%, and 74.6%, respectively. The small changes in regression from the original model data in Figure 8 indicates that the analytics methodology was able to incorporate new drug chemistries with minor impacts on the models. This confirms the robustness of the model and its capability to screen drug and polymer chemistries not included in the model development.
DISCUSSION
Due to the wide diversity of microbial infections, nanomedicines need to be customizable.
Infections that are responsive to antibiotics may benefit from sustained release-skewing 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 formulations by leveraging the dose sparing properties, limiting the risk of off-target effects, reducing the number of administrations, and enhancing patient compliance. 4, 8, 39 Polyanhydride nanoparticles represent an attractive and adaptable nanomedicine platform by virtue of their tunable degradation and payload release rates, 25, 40 high biocompatibility, 41, 42 and efficient internalization by phagocytic cells. 7 Predictive analytics approaches have the potential to accelerate nanomedicine clinical translation, but the application of such informatics and data mining techniques to nanomedicine design has been slow to develop. 13 To date, the majority of such efforts has focused on either linear dimensionality reduction through PCA and regression through PLS, 27 which provides insight into relationships between formulations and variables but has limited capacity to capture nonlinear behavior, or else artificial neural network "black box" models, [43] [44] [45] which can capture nonlinear behavior but obscure interpretation of the structure of the model and dataspace. As the long-term goal of this research is to facilitate rational design of nanomedicine formulations, interpretation of the relationships between formulations is important. Accordingly, the dimensionality reduction approach was selected for this research, and paired with graph theory mapping to overcome the linearity limitations of PCA.
A hybrid data mining approach was employed to deconvolute the complex polymer and drug relationships and develop QSPRs that describe release kinetics and encapsulation efficiency. We correlated antibiotic release properties from varying polyanhydride chemistries, encapsulated drug types, and drug loading within the nanoparticles. Through PCA analysis, we showed that release properties are dependent on both copolymer chemistry properties and drug properties, with polymer properties being more important. VIP analysis identified key polymer and drug descriptors that predicted drug release and encapsulation properties, but PCA was insufficient to predict release behavior from these formulations. The physicochemical properties of compounds influence their distribution, either in blood plasma or a polymer matrix. To this effect, VIP analysis ( Figure 6 ) indicated that the descriptors most strongly correlated with release properties were both polymer and drug properties. This is expected, as favorable mixing thermodynamics allows distribution of the drugs inside the polymer device. 10, 46 In polyanhydride nanoparticles, such a distribution allows an erosioncontrolled release profile, which tends toward sustained release. 9, 11 In contrast, poor mixing between the polymer and drug induces thermodynamic partitioning of the drug into polymer microdomains and/or localization at the particle surface, which skews the release profile toward 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 a high-burst, diffusion-dominated regime. 11 Many of these same drug properties were correlated with encapsulation efficiency, supporting the notion that polymer-drug mixing influences the carrying capacity of delivery devices. As empty polyanhydride nanoparticles have a moderately negative zeta potential, 23 the strong negative correlation between zeta potential and encapsulation efficiency could reflect a strong surface localization of positively charged drugs. If this were the case, however, we would expect a strong positive correlation between zeta potential and the twohour burst release, which was not observed. Regardless, the predictive power of this descriptor could support the use of zeta potential as a quality control metric to ensure consistent encapsulation efficiencies of lead formulations. While it is not surprising that these drug properties affect encapsulation and release kinetics, this informatics analysis provides a sense of their relative impact. Reducing the data space in this way can help guide rational selection of antibiotic and polymer carrier pairs for nanomedicine formulations. These observations underline the complexity of these relationships and provide support for the use of data analytics approaches to enable rational design of nanomedicines.
It should be noted that we can only confidently make quantitative predictions in chemical spaces represented in our training data. While the additional testing of drugs containing sulfur, which was not represented in our training data, resulted in approximately no change in accuracy, materials that have unique behavior but with chemistries outside our training data may not be quantitatively described by this approach. However, even in these cases, our approach has significant impact. While the objective for the systems described by our training data is to predict properties with high accuracy, the objective for systems containing groups and elements not in our training data is to identify polymer and drug combinations which have the most promising 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 5. CONCLUSIONS A multivariate data analytics approach was used to correlate drug release profiles from nanomedicine formulations based on different polyanhydride chemistries, encapsulated antibiotic drug type, and varying drug loading. We showed that both drug and polymer properties influence the drug encapsulation efficiency within the nanoparticles, the prevalence of burst in the drug release profile, and the slope of post-burst release. Polymer and drug properties that significantly impacted drug encapsulation efficiency and release kinetics were identified and defined a minimum descriptor set. The informatics analysis captured and preserved non-linear behavior governing relationships between drug type, polymer chemistry, and nanoparticle release properties, enabling interrogation of nanomedicine design pathways. We developed predictive 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 models for drug release kinetics of untested drugs, using data from the Drugbank database and nano-carrier characterization as inputs. Release kinetics predictions of two drugs containing atoms not included in the model showed good agreement with experimental results, validating the model and indicating its potential to virtually explore new polymer and drug pairs not included in training data set. The models were shown to be robust after inclusion of these new formulations in that there were no significant changes in the model regressions. This multilinear modeling approach provides the first steps towards development of a framework that can be used to rationally design nanomedicine formulations by selecting the appropriate carrier for a drug payload to program desirable release kinetics profiles. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 †If an author's address is different than the one given in the affiliation line, this information may be included here. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
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